Compare UCTT & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UCTT | CRNX |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.9B |
| IPO Year | 2004 | 2018 |
| Metric | UCTT | CRNX |
|---|---|---|
| Price | $118.82 | $36.70 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $97.33 | $76.75 |
| AVG Volume (30 Days) | ★ 1.3M | 1.0M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,734,500,000.00 | $1,039,000.00 |
| Revenue This Year | $19.18 | $720.10 |
| Revenue Next Year | $17.36 | $184.67 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $21.28 | $25.83 |
| 52 Week High | $125.00 | $57.99 |
| Indicator | UCTT | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 61.83 | 52.34 |
| Support Level | $24.51 | $33.14 |
| Resistance Level | N/A | $44.89 |
| Average True Range (ATR) | 8.13 | 1.63 |
| MACD | 0.93 | 0.29 |
| Stochastic Oscillator | 80.94 | 68.55 |
Ultra Clean Holdings Inc, through its subsidiaries, manufactures and supplies production tools, modules, and subsystems for the semiconductor capital equipment industry. The product includes precision robotic solutions, gas delivery systems, and a variety of industrial and automation production equipment products; subsystems include wafer cleaning subsystems, chemical delivery modules, top-plate assemblies, frame assemblies, and process modules. Its customer base includes firms in the semiconductor capital equipment industry, medical, energy, industrial, flat panel, and research equipment industries. It has two segments: Products and Services. Its principal markets are the Americas, Asia Pacific, and EMEA.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.